Antibiotic De-Escalation

Critical Care Clinics

Volumn 27, Issue 1, 2011, Pages 149-162

  Masterton, Robert G ^a  

^a AYR HOSPITAL   (United Kingdom)

Author keywords

Antimicrobial stewardship; Antimicrobial streamlining; De escalation

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIINFECTIVE AGENT; CARBAPENEM; IMIPENEM; MEROPENEM; POLYPEPTIDE ANTIBIOTIC AGENT;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG DOSE DE ESCALATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; ESCHERICHIA COLI INFECTION; HOSPITAL INFECTION; HUMAN; LENGTH OF STAY; META ANALYSIS; MORTALITY; PNEUMONIA; PNEUMONIA SEVERITY INDEX; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SEPSIS; SEPTICEMIA; SUPERINFECTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-INFECTIVE AGENTS; CROSS INFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; HUMANS; INTENSIVE CARE UNITS; PRACTICE GUIDELINES AS TOPIC; SEPSIS;

EID: 78649948667     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2010.09.009     Document Type: Review

References (24)

1. Theuretzbacher U. Future antibiotics scenarios: is the tide starting to turn?. Int J Antimicrob Agents 2009, 34:15-20.
2. Masterton R.G. The new treatment paradigm and the role of carbapenems. Int J Antimicrob Agents 2009, 33:105-110.
3. Dellit T.H., Owens R.C., McGowan J.E., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.
4. Kollef M.H. Optimizing antibiotic therapy in the intensive care unit setting. Crit Care 2001, 5:189-195.
5. Lisboa T., Rello J. De-escalation in lower respiratory tract infections. Curr Opin Pulm Med 2006, 12:364-368.
6. Petrosillo N., Drapeau C.M., Agrafiotis M., et al. Some current issues in the pharmacokinetics/pharmacodynamics of antimicrobials in intensive care. Minerva Anestesiol 2010, 76:509-524.
7. Park D.R. Antimicrobial treatment of ventilator-associated pneumonia. Respir Care 2005, 50:932-952.
8. Vidaur L., Sirgo G., Rodriguez A.H., et al. Clinical approach to the patient with suspected ventilator-associated pneumonia. Respir Care 2005, 50:965-974.
9. Singh N., Rogers P., Atwood C.W., et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162:505-511.
10. Rello J., Vidaur L., Sandiumenge A., et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004, 32:2183-2190.
11. Soo Hoo G.W., Wen Y.E., Nguyen T.V., et al. Impact of clinical guidelines in the management of severe hospital acquired pneumonia. Chest 2005, 128:2778-2787.
12. Álvarez-Lerma F., Alvarez B., Luque P., et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Critical Care 2006, 10:R78.
13. Kollef M.H., Morrow L.E., Niederman M.S., et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006, 129:1210-1218.
14. Leone M., Garcin F., Bouvenot J., et al. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med 2007, 35:379-385.
15. Giantsou E., Liratzopoulos N., Efraimidou E., et al. De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 2007, 33:1533-1540.
16. Eachempati S.R., Hydo L.J., Shou J., et al. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients?. J Trauma 2009, 66:1343-1348.
17. Donaldson A.D., Barkham T. De-escalation for amoxicillin-susceptible Escherichia coli: easier said than done. J Hosp Infect 2010, 74:304-305.
18. De Waele J.J., Ravyts M., Depuydt P., et al. De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality?. J Crit Care 2010, [Epub ahead of print].
19. Schlueter M., James C., Dominguez A., et al. Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia. Infection 2010, 38(5):357-362.
20. Fox BC, Fish J, Zheng L, et al. Prospective study of de-escalation of antimicrobial therapy in an ICU [abstract 217]. In: Program and abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America [Boston]: Infectious Diseases Society of America, Arlington (VA), 2004: 73.
21. Kumar A., Safdar N., Kethireddy S., et al. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 2010, 38:1651-1664.
22. Sartelli M. A focus on intra-abdominal infections. World J Emerg Surg 2010, 5:9.
23. Lesprit P., Landelle C., Girou E., et al. Reassessment of intravenous antibiotic therapy using a reminder or direct counselling. J Antimicrob Chemother 2010, 65:789-795.
24. Lichtenstern C., Nguyen T.H., Schemmer P., et al. Efficacy of caspofungin in invasive candidiasis and candidemia-de-escalation strategy. Mycoses 2008, 51(Suppl 1):35-46.